Access count of this item: 158
|Other Titles:||THE EFFECT OF HACHIMIJIOGAN ON PATIENTS WITH IMPOTENCE|
|Author's alias:||Nishizawa, Yoshio|
|Abstract:||he effect of Hachimijiogan on 37 patients who were 18~71 years old and had impotency as classified by Kimura (22 patients had psycogenic problems and 15 patients did not feel an orgasm), 37 age-matched healthy individuals served as the control group. The patients and control group were given the Cornell Medical Index (CMI) test and Yatabe-Guilford CY-G) test. The patients who scored III and IV on the CMI test and Band E on the Y-G test all had psycogenic problems. Questionaires were handed out before and 4 weeks after the administration of Rachimijiogan. During this experimental protocol, no other drugs were taken. Blood testosterone level and 17KS and 17 ORCS contents in the urine were determined and routine laboratory blood analysis performed before and after drug administration to assess drug efficacy on the patients and normal control subjects. In impotent patients in the psycogenic group, increased sexual desire, increased erectile activity by viewing sexually exciting material, increased erectile activity during sexual intercourse or masturbation, augumentation of morning erection and/or increased frequency of morning erection, longer duration of sexual intercourse, decreased sense of fatigue after sexual intercourse, and increased sexual satisfaction in partner was observed in 25.0%, 16.7, 58.3, 58.3, 25.0, 25.0 and 16.7%, respectively. On the other hand, in the group not feeling orgasms, the percentages for the same items were 25.0, 25.0, 25.0, 50.0, 25.0, 25.0 and 0, respectively. In the normal control group, the percentages were 24.0, 20.0, 56.0, 32.0, 16.0, 28.0, and 12.0%, respectively. Efficacy rate of Rachimijiogan was 43.2% for the impotent patients and 67.5% for the control go up (32.4% for the psycogenic patients, 10.8 % for the patients not feeling orgasms). For the psycogenic group there was marked effectiveness, moderate effectiveness, slight effectiveness and no effectiveness in 18.9, 13.5, 10.8 and 16.2%. The respective percentages for the patients not feeling orgasms was 5.4, 5.4, 8.1, and 21. 6 %. The respective percentages for the normal group was 43.2, 24.3, 10.8, and 21. 6%. Of the impotent patients, many of those under 30 years old had psycogenic problems and many of those over 40 years old did not feel an orgasm. The efficacy rate for Hachimijiogan was higher for younger impotent patients, that is, those with psycogenic problems than for older importent patients, that is, those not feeling an orgasm. More impotent patients scored III and IV on the CMI than the control group and the efficacy rate (over slightly effective) was 60.0%. The efficacy rate of the control group was 77.8%. The importent patients in the Band E group of the Y-G test had an efficacy rate of 100%. The efficacy rate for the control group was 73.7%. The drug was effective for 73.3%, 41. 7% and 0% of the impotent patients who were slender, normal and obese in build, respectively. But the effectiveness wg was 60.0, 66.6, and 60.0 % for the normal control group with the respective builds. Side effects were seen only in the impotent patients and normal individuals who were obese. They were frequent micturition in 5 cases, abdominal pain in 2 cases, upset stomach in 3 cases, nausea in 1 case, nasal bleeding in 2 cases, hotness of face in 1 case. Hachimijiogan had no effect on 17KS or 17 OHCS in the urine or on serum testosterone or routine laboratory tests. These results suggest that Hachimijiogan is an effective drug for the improvement of impotence in patients who are not obese without causing any side effects.|
|Appears in Collections:||Vol.29 No.5|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.